Cell cycle regulation in adrenocortical carcinoma

• Type: Another Publication in an International Scientific Journal
• Date: 2018

Authors

Pereira, SS (Author) ICBAS; Monteiro, M (Author) ICBAS; Bourdeau, I (Author) Other; Lacroix, A (Author) Other; Pignatelli, D (Author) Other

Journal

Title: European Journal of Endocrinology

Vol. 179

Pages: R95-R110

ISSN: 0804-4643

Publisher: BioScientifica Ltd.

Indexing

ISI Web of Knowledge - 13 Citations

Scopus - 13 Citations

Other information

Authenticus ID: P-00P-E4W

DOI: 10.1530/eje-17-0976

Abstract (EN): Adrenocortical carcinomas (ACCs) are rather rare endocrine tumors that often have a poor prognosis. The reduced survival rate associated with these tumors is due to their aggressive biological behavior, combined with the scarcity of effective treatment options that are currently available. The recent identification of the genomic alterations present in ACC have provided further molecular mechanisms to develop consistent strategies for the diagnosis, prevention of progression and treatment of advanced ACCs. Taken together, molecular and genomic advances could be leading the way to develop personalized medicine in ACCs similarly to similar developments in lung or breast cancers. In this review, we focused our attention to systematically compile and summarize the alterations in the cell cycle regulation that were described so far in ACC as they are known to play a crucial role in cell differentiation and growth. We have divided the analysis according to the major transition phases of the cell cycle, G1 to S and G2 to M. We have analyzed the most extensively studied checkpoints: the p53/Rb1 pathway, CDC2/cyclin B and topoisomerases (TOPs). We reached the conclusion that the most important alterations having a potential application in clinical practice are the ones related to p53/Rb1 and TOP 2. We also present a brief description of on-going clinical trials based on molecular alterations in ACC. The drugs have targeted the insulin-like growth factor receptor 1, TOP 2, polo-like kinase1, cyclin-dependent kinase inhibitors, p53 reactivation and CDC25.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 16